Abstract: A method is disclosed for producing sulphate or phosphate-based fertilizer from hydrogen sulphide. The method involves feeding a stream containing a substantial volume of hydrogen sulphide and air to a furnace, where it is burned to produce a sulphur dioxide rich gas stream. The sulphur dioxide rich gas stream is then fed to a reactor to produce a sulphuric acid stream and a waste stream comprising carbon dioxide, nitrogen, oxygen, trace impurities and trace amounts of unreacted sulphur dioxide. The sulphuric acid stream is finally converted to a sulphate or phosphate-based fertilizer.

Abstract: A starter fertilizer product combining manganese with P and Zn creates a previously unknown synergy in early plant growth and plant health.

Abstract: A composition based on three strains of microorganisms to promote plant growth and serve as a plant protection product to protect plants from damaging influences including plant disease, pests or insects. The composition is comprised of Paenibacillus polymyxa M10, Azospirillum canadense B2, and Bacillus pumilus L13. A mineral mix is used to maintain the microorganism viable for a long time, maintaining high efficacy as a biopesticide and biofertilizer. The mineral mix combined with the fermented microorganisms is then further combined with a nutritional additive to enhance the biofertilizing and biopesticidal features of the composition. The resulting composition can be applied to plants in liquid form or to the soil in solid form.

Abstract: The invention relates to a process for converting hydrocarbons into unsaturated products such as acetylene and/or ethylene. The invention also relates to converting acetylene to olefins such as ethylene and/or propylene, to polymerizing the olefins, and to equipment useful for these processes.

Abstract: A process for component separation in a polymer production system, comprising separating a polymerization product stream into a gas stream and a polymer stream, wherein the gas stream comprises ethane and unreacted ethylene, distilling the gas stream into a light hydrocarbon stream, wherein the light hydrocarbon stream comprises ethane and unreacted ethylene, contacting the light hydrocarbon stream with an absorption solvent system, wherein at least a portion of the unreacted ethylene from the light hydrocarbon stream is absorbed by the absorption solvent system, and recovering a waste gas stream from the absorption solvent system, wherein the waste gas stream comprises ethane, hydrogen, or combinations thereof.

Abstract: This invention is directed to an improvement in the process for the production of alkylaromatic compounds that results in lower levels of residual unreacted materials in the final product. This invention comprises: 1) alkylation of an aromatic compound with an alkylating agent and a catalyst to produce an effluent stream comprising an alkylaromatic compound and unreacted materials; 2) heating the effluent stream; 3) stripping the effluent stream in a stripping device in the presence of steam; 4) separating a stripping stream from the stripping device, the stripping stream rich in unreacted materials; and 5) separating a product stream from the stripping device, the product stream rich in alkylated aromatic compound.

Abstract: A charcoal ignition fluid that is composed of a blend of bio-based hydrocarbons for the ignition of charcoal in both briquette and lump forms. The charcoal ignition fluid utilizes linear and branched alkanes produced by means of variations of the Fischer-Tropsch process that incorporates raw materials that are generally recognized as more sustainable than petroleum oil. The process for producing the charcoal ignition fluid deoxygenates fatty acids, esters, etc. by removing and fully saturating all double bonds in the bioactive raw materials.

Abstract: This disclosure relates to processes of making 1,3,3,3-tetrafluoropropene. The processes involve dehydrofluorinating 1,1,1,3,3-pentafluoropropane in vapor phase in the presence of a catalyst comprising a metal compound supported on alumina to produce a product mixture comprising 1,3,3,3-tetrafluoropropene, wherein said metal compound is selected from the group consisting of salts of sodium, potassium, zinc, magnesium, calcium, cobalt, copper, and chromium, and mixtures thereof.

Abstract: The present invention relates to a method for preparing fluorinated olefin compounds, in particular (chloro)fluoropropenes and (chloro)fluorobutenes, and specifically, the fluorinated compound 2,3,3,3-tetrafluoro-1-propene, including at least one step of fluorination, in the gaseous phase, with HF and at least one compound selected from the halopropenes having formula the CX3CHClCH2X and the halopropenes having the formulas CX3CC1?CH2, CClX2CCl?CH2 and CX2?CClCH2X, where X is, independently, a fluorine or chlorine atom, in the presence of oxygen and a fluorination catalyst suspended in a fluidized-bed reactor.

Abstract: A butanol production system and method of producing refined mixed butanols from water and mixed butenes. The system includes an internal baffle single pass reactor, a separation system and an exterior motion driver. The reactor has baffled cells. The separations system is operable to separately selectively separate water and mixed butenes from the crude product such that a refined mixed butanols is produced. The exterior motion driver is operable to induce unsteadiness in the fluid flow of the process fluid through the reactor. A method for producing refined mixed butanols includes introducing mixed butenes, water and a butene hydration catalyst into the reactor, operating the butanol production system such that the external motion driver induces unsteadiness in the process fluid flow and the reaction of mixed butenes and water occurs in the presence of the butene hydration catalyst such that mixed butanols form.

Abstract: A method of producing an alcohol compound from an organic acid compound including the step of heating a solution of the organic acid compound in the presence of a heterogeneous catalyst including transition metal supported upon a cross-linked functional polymer.

Abstract: This specification discloses a complete method to manufacture polyester articles from freshly harvested ligno-cellulosic biomass. The process steps include pretreating the biomass and the converting the lignin to one of several possible organic steams by deoxygenating and dehydrogenating the lignin in the presence of a Raney Nickel catalyst, separating the organics, and then processing the organics into polyester feedstocks and converting those feedstocks to polyester.

Abstract: Described herein are compositions having (a) at least 99 wt % phenol; and (b) 0.1 wppm to 1000 wppm of at least one of the following components: bicyclohexane, cyclohexylbenzene, methylcyclopentylbenzene, hydroxycyclohexanone, cyclohexenone, cyclohexanol, cyclohexanone, cyclohexanedione, benzoic acid, hexanal, and methycyclopentanone, wherein the wt % and wppm are based upon the total weight of the composition.

Abstract: The invention is a process for producing a propylene glycol monoalkyl ether which comprises first reacting propylene oxide and an alcohol in the presence of an alkali or alkaline earth metal alkoxide catalyst to produce an alkoxylation mixture comprising propylene glycol monoalkyl ether; distilling the alkoxylation mixture to produce a first overhead stream comprising propylene oxide and alcohol and a first bottoms stream comprising propylene glycol monoalkyl ether; and then distilling the first bottoms stream to produce purified propylene glycol monoalkyl ether as a second overhead stream. The reaction and/or one or more of the distillation steps occur in the presence of an alkali metal borohydride. The process produces propylene glycol monoalkyl ether with low UV absorbance and reduced carbonyl impurities.

Abstract: Process for the preparation of dimethyl ether comprising the steps of: a) providing a methanol containing feed stock; b) introducing the feed stock into a reaction zone within a gas cooled dimethyl ether reactor and passing the feed stock through the reaction zone; c) introducing a cooling gas stream into a cooling space within the gas cooled dimethyl ether reactor; d) reacting the feed stock in the reaction zone in presence of a catalyst being active in the dehydration of methanol to dimethyl ether to obtain a reactor effluent comprising dimethyl ether.

Abstract: Provided in the present invention is a method for synthesizing 2,7-dimethyl-2,4,6-octatriene-1,8-dialdehyde.

Abstract: The disclosure concerns a method for preparing acrolein from glycerol, according to which a dehydration of the glycerol is carried out in the presence of a catalyst MWOA, wherein MWO represents a mixture of simple oxides and/or mixed oxides of tungsten and at least one metal M selected among zirconium, silicon, titanium, aluminium and yttrium, and A represents one or several Lewis base(s), one said Lewis base being of the formula B(R1)p(R2)q(R3)r, wherein B is an element selected among C, S, P, O, N and halides, R1, R2 and R3 represent, independently of each other, H, a C1-C6 alkyl group, O, OH or OR wherein R represents a C1-C6 alkyl group, and the sum of p, q and r varies from 0 to 4.

Abstract: The invention provides compositions and methods for the treatment of glomerulonephritis. In one embodiment, the invention provides a compound of formula (I) R-L-CO—X??(I) (wherein R is a C10-24 unsaturated hydrocarbon group optionally interrupted by one or more heteroatoms or groups of heteroatoms selected from S, O, N, SO, SO2, said hydrocarbon group comprising at least 4 non-conjugated double bonds; L is a linking group forming a bridge of 1 to 5 atoms between the R group and the carbonyl CO; and X is an electron withdrawing group) or a salt thereof for use in the treatment of glomerulonephritis.

Abstract: Curcumin analogues and methods are provided for treatment of disease.

Abstract: A process utilizing nitric acid and oxygen as co-oxidants to oxidize aldehydes, alcohols, polyols, preferably carbohydrates, specifically reducing sugars to produce the corresponding carboxylic acids.

Abstract: The production of maleic acid and fumaric acid (or the anhydride form of either, maleic anhydride) via gas-phase, oxidative cleavage of levulinic acid in a single packed bed reactor over a reducible oxide catalyst. The production may be carried out in an initial mixing vessel into which levulinic acid is continuously charged and mixed with both inert (He, N2, Ar, etc.) and oxidizing (O2, air, etc.) gases. The feed stream can then be safely heated to reaction temperature, which generally ranges from 200-500° C., without initiating polymerization, in a second stage preheater that thermally equilibrates the gaseous mixture of LA, O2, and inert diluent and fed to a third stage catalytic reactor for final processing.

Abstract: The present invention pertains to a process for separating monochloroacetic acid and dichloroacetic acid from one another via extractive distillation using (a) an extractive agent that is chemically stable and has a BF3 affinity of between 65 kJ/mole and 110 kJ/mole and (b) an organic solvent that is either an acid with a lowest pKa of between 3.0 and 6.

Abstract: The invention relates to a process for preparing a compound represented by the formula 1 which compound may optionally be further mono- or di- substituted with halogen atoms, alkyl groups having 1 to 4 C— atoms and/or alkoxy groups having 1 to 4 C— atoms, wherein R is methyl or ethyl group, comprising the step of: contacting a corresponding compound represented by the formula 2 which compound is not further substituted or further mono- or di- substituted in corresponding positions with halogen atoms, alkyl groups having 1 to 4 C— atoms and/or alkoxy groups having a to 4 C-atoms, with an alkylating agent, wherein the alkylating agent is a compound of the formula (RO)2SO2 or RX, wherein R has the above meaning and X is halogen, in the presence of a bis-quaternary ammonium salt or a polymeric quaternary ammonium salt, in a two-phase system of an aqueous solution of a base and an organic solvent.

Abstract: The present invention provides novel aspirin derivatives useful for preventing and/or treating cancer. The novel compounds of this invention may be particularly useful for the prevention and/or treatment of cancers affecting the gastrointestinal system, such as colorectal cancer.

Abstract: The instant invention provides a process for separating one or more aliphatic diamines from reductive amination reaction solvents and impurities, and aliphatic diamines obtained via such a process. The process for separating one or more aliphatic diamines from reductive amination reaction solvents and impurities according to the instant invention comprises the steps of: (1) feeding one or more cycloaliphatic cyanoaldehydes, hydrogen, ammonia, and optionally one or more solvents into a continuous reductive amination reactor system; (2) contacting said one or more cycloaliphatic cyanoaldehydes, hydrogen, and ammonia with each other in the presence of one or more heterogeneous metal based catalyst systems at a temperature in the range of from 80° C. to about 160° C.

Abstract: A method for producing a narrow molecular weight distribution polyalkylene glycol derivative having an amino group at an end under mild conditions. A method for producing a compound of the general formula (1): CH3O(CH2CH2O)nCH2CH2CH2NH2 (wherein n is an integer of 1 to 450) comprises the following steps of: 1) a step of producing a compound of the general formula (3): CH3O(CH2CH2O)k-1CH2CH2O?M+ from a compound of the general formula (2): CH3O(CH2CH2O)kH (wherein k is an integer of 2 to 5); 2) a step of producing a compound of the general formula (4): CH3O(CH2CH2O)n-1CH2CH2O?M+ from a compound of the general formula (3); 3) a step of reacting a compound of the general formula (4) with acrylonitrile to obtain a compound of the general formula (5): CH3O(CH2CH2O)nCH2CH2CN; and 4) a step of reducing a compound of the general formula (5) to obtain a compound of the general formula (1).

Abstract: The present invention relates uses of an S1P receptor modulator such as 2-substituted 2-amino-propane-1,3-diol or 2-amino-propanol derivatives, e. g. a compound comprising a group of formula X for the treatment or prevention of neo-angiogenesis associated with a demyelinating disease, e.g. multiple sclerosis.

Abstract: This invention provides a compound having the structure wherein ?, ?, X, Y, and R1-R11 are defined herein. This invention also provides a pharmaceutical composition comprising the above compounds, a method of inhibiting the activity and/or levels of a matrix metalloproteinase (MMP), a method of inhibiting the production of a cytokine in a population of cells, a method of inhibiting the production of a growth factor in a population of cells, and a method of inhibiting NF?-B activation in a population of cells.

Abstract: A process of producing N-acyl amino acid based surfactants of Formula I, wherein, R is selected from C6 to C22 alkyl group, R1 is selected from H, C1 to C4 alkyl, R2 is selected from all groups on ? carbon of natural amino acids, R3 is selected from COOX, CH2—SO3X, X is selected from Li+, Na+ or K+. The process comprising steps of: A) preparing fatty acid chlorides by halogenating fatty acids with either phosgene or thionyl chloride in the presence of catalytic amount of same or other N-acyl amino acid surfactant of Formula I or anhydrides of same surfactant; and B) reacting fatty acid chloride of step (A) with an amino acid in the presence of a base.

Abstract: The present invention is directed to a novel process for the preparation of protected L-alanine derivatives, useful as intermediates in the synthesis of compounds useful as mu/delta opioid modulators.

Abstract: The present invention provides novel process for the preparation of renin inhibitor Aliskiren or its derivatives, and its pharmaceutically acceptable salts. The present invention also provides novel intermediates used in the preparation of Aliskiren.

Abstract: The present invention provides a process for isolating tigecycline which process comprises the step of spray drying a solution of tigecycline in a solvent. Preferably the solvent is water or an organic solvent. In another aspect, there is provided tigecycline obtainable by spray drying, particularly in amorphous form. In particular, the invention provides tigecycline obtainable by spray drying according to the process of the invention.

Abstract: The present invention provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof. Also, the present invention provides a pharmaceutical composition comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. The present invention further provides methods for treating abdominal aortic aneurysm or atherosclerosis comprising administering a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Formula (I) or pharmaceutically acceptable salt thereof.

Abstract: The present invention refers to the preparation of 3-cyano-3,5,5-trimethylcyclohexanone (isophorone nitrile, abbreviation IPN) using a calcium alkoxide, particularly calcium ethoxide, as catalyst.

Abstract: Peripherally restricted inhibitors of fatty acid amide hydrolase (FAAH) are provided. The compounds can suppress FAAH activity and increases anandamide levels outside the central nervous system (CNS). Despite their relative inability to access brain and spinal cord, the compounds attenuate behavioral responses indicative of persistent pain in rodent models of inflammation and peripheral nerve injury, and suppresses noxious stimulus-evoked neuronal activation in spinal cord regions implicated in nociceptive processing. CBi receptor blockade prevents these effects. Accordingly, the invention also provides methods, and pharmaceutical compositions for treating conditions in which the inhibition of peripheral FAAH would be of benefit. The compounds of the invention are according to the formula (I): in which R1 is a polar group. In some embodiments, R1 is selected from the group consisting of hydroxy and the physiologically hydro lysable esters thereof.

Abstract: The present invention relates generally to novel methods of preparing compounds such as sulfate betaines by reacting an amine with a cyclic (poly)glycerol sulphate (CGS) compound and the compound such as sulfate betaine products obtained by using the same.

Abstract: Compounds of Formula I are disclosed: wherein L, A, R1, R2, R3A, R3B, R4A, R4B, R5, R6 and R7 are defined herein. The compounds encompassed by Formula I include compounds which are HIV protease inhibitors and other compounds which can be metabolized in vivo to HIV protease inhibitors. The compounds and their pharmaceutically acceptable salts are useful for the prophylaxis or treatment of infection by HIV and the prophylaxis, treatment, or delay in the onset of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.

Abstract: Described herein is a composition according to formula I or its precursor, formula II: CX1X3?CX2—(R1)p—CZ1 Z2-SO2M (I) wherein X1, X2, and X3 are independently selected from H, F, Cl, Br, I, CF3 and CH3, and wherein at least one of X1, X2, or X3 is a H; R1 is a linking group; Z1 and Z2 are independently selected from F, Cl, Br, I, CF3, and a perfluoroalkyl group; p is 0 or 1; and M is a cation; and CX4X1X3—CX5X2—(R1)p—CZ1Z2-SO2M (II) wherein X1, X2, and X3 are independently selected from H, F, Cl, Br, I, CF3 and CH3, wherein at least one of X1, X2, or X3 is a H, and X4 and X5 are independently selected from H, F, Cl, Br and I; R1 is a linking group; Z1 and Z2 are independently selected from F, Cl, Br, I, CF3, and a perfluoroalkyl group, p is 0 or 1; and M is selected from F, and a cation.

Abstract: Provided herein are new processes for the preparation of aminosulfone intermediates for the synthesis of 2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, which is useful for preventing or treating diseases or conditions related to an abnormally high level or activity of TNF-?. Further provided herein are processes for the commercial production of (S)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethylamine.

Abstract: The present invention relates to a new method for the preparation of (3S,3S?) 4,4?-disulfanediylbis(3-aminobutane 1-sulfonic acid) in five steps from (S)-ethyl 2-(benzyloxycarbonylamino)-4-(neopentyloxysulfonyl)butanoate A.

Abstract: Disclosed are intermediates of Sitagliptin, a preparation process thereof, and a process for synthesizing Sitagliptin using these intermediates. Sitagliptin is synthesized by using chiral amino compounds as a raw material, without having to build a chiral center with a chiral asymmetric catalytic hydrogenation, and high-pressure hydrogenation is avoided.

Abstract: Disclosed is a compound of formula (I) wherein ‘a’ and R1-R5 are as described herein, as a modulator of nicotinic acetylcholine receptors particularly the ?7 subtype, in a subject in need thereof, as well as analogs, prodrugs, isotopically substituted analogs, metabolites, pharmaceutically acceptable salts, polymorphs, solvates, isomers, clathrates, and co-crystal thereofs, for use either alone or in combinations with suitable other medicaments, and pharmaceutical compositions containing such compounds and analogs. Also disclosed are a process of preparation of the compounds and the intended uses thereof in therapy, particularly in the prophylaxis and therapy of disorders such as Alzheimer's disease, mild cognitive impairment, senile dementia, and the like.

Abstract: The invention is directed to compounds according to formula (I): where R1 is L1C(O)OT or L1C(O)OL2C(O)OT; R2 is a substituted or unsubstituted C1-C10 alkyl, C2-C10 alkenyl, or C2-C10 alkynyl, or R1; n is an integer from 0 to 5; each R3 is independently halogen or R2; R4 and R5 are independently H, halogen, CN or CF3; L1 and L2 are each independently a bond, a substituted or unsubstituted C1-C10 alkylene, C2-C10 alkenylene, or C2-C10 alkynylene; and T is H, a substituted or unsubstituted C1-C10 alkyl, C2-C10 alkenyl, or C2-C10 alkynyl, nitrophenol, or cyclopropyl. The invention is also directed to a pharmaceutical composition comprising a compound according to formula (I) and a pharmaceutically acceptable carrier, and to methods for providing anesthesia in mammals by administering such a pharmaceutical composition.

Abstract: The invention relates to processes and intermediates for preparing compounds of formula I: where a, R1, and R3-6 are as defined in the specification, or a salt thereof. The compounds of formula I are serotonin and norepinephrine reuptake inhibitors.

Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.

Abstract: Provided herein are 2,5-disubstituted arylsulfonamide CCR3 antagonists, e.g., compounds of Formula I, and pharmaceutical compositions thereof: Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a CCR3-mediated disorder, disease, or condition.

Abstract: The present invention provides heterocyclic derivatives that modulate the activity of stearoyl-CoA desaturase. Methods of using such derivatives to modulate the activity of stearoyl-CoA desaturase and pharmaceutical compositions comprising such derivatives are also encompassed.

Abstract: The invention relates to N-substituted nicotinamide compounds of Formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of Formula I, and methods for the treatment of migraine and neurologic diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of epilepsy, migraine, Post Herpetic Neuralgia, Acute and Chronic Pain, Alzheimer's disease, Creutzfeld Disease, familial amyloid polyneuropathy, parkinson's disease, fibromyalgia syndrome.

Abstract: The present application relates to novel substituted dicyanopyridines, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, preferably for the treatment and/or prophylaxis of cardiovascular disorders.

Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, A and n are as described herein, compositions including the compounds and methods of using the compounds.